CAM2029 is a novel depot formulation of octreotide, a somatostatin analogue, administered subcutaneously once monthly.

ADRX-0405 is a novel antibody-drug conjugate targeting STEAP1, and a phase 1a/b study will investigate the agent for the ...

Phase 2 filing on track for Q1 2025 "The acceptance of our third U.S. IND is an important milestone for Aligos,” said ...

NanoViricides, Inc. (NYSE Amer.: NNVC ) (the “Company”), a clinical stage global leader in broad-spectrum antiviral ...

LNZ100 is a single-use, once-daily eye drop containing aceclidine, a small molecule acetylcholine receptor agonist that causes miosis.

In Teva Branded Pharm. Prods. R&D v. Amneal Pharms. of N.Y., LLC, the US District Court for the District of New Jersey ordered Teva to delist ...

The new drug application resubmission of rivoceranib/camrelizumab in the first line in unresectable or metastatic ...

Pharmacists insist no policies have changed as doctors try to determine why their patients have to chase down medication ...

At the Neurocritical Care Society's (NCS) 22nd Annual Meeting this week, a University of Cincinnati researcher presented ...

LENZ Therapeutics said the submission for the treatment of presbyopia is supported by the positive data results from a Phase 3 study. Aceclidine is a new chemical entity in the U.S. and isn't approved ...

Learn how to effectively navigate the challenges of CMC in breakthrough drug development. Discover key strategies here.

The regulator has delayed its respective decision dates on whether to grant full approval to Amgen’s Lumakras in metastatic ...